Jan Fawcett, A., Rush, J., Vukelich, J., Diaz, S.H., Dunklee, L., Romo, P., Yarns, B.C. and Escalona, R. (2016) Clinical Experience with High-Dosage Pramipexole in Patients with Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression. American Journal of Psychiatry, 173, 107-111.
https://doi.org/10.1176/appi.ajp.2015.15060788

has been cited by the following article:

• TITLE: Pramipexole in Treatment Resistant Depression: A Case Review

  AUTHORS: Nada Abdallah, Jeffrey Kahn

  KEYWORDS: Pramipexole, Treatment Resistant Depression, Augmentation, Dopamine Agonism, Geriatric Psychiatry

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.14 No.7, July 27, 2023

  ABSTRACT: Pramipexole is a dopamine agonist used in the treatment of Parkinson’s disease and Restless legs syndrome. Although off-label, the use of Pramipexole as an adjunct therapy in treatment resistant depression has recently been documented in the literature with promising results. We present a 75-year-old male with MDD who has failed trials of SSRIs, SNRIs, TCAs, SGA, TMS, Ketamine, and ECT who was initiated on Pramipexole. We discuss, based on existing literature, the probability of a favorable long-term response to Pramipexole and the potential side effects for our patient. We also highlight the need for future studies designed to test the efficacy of Pramipexole in geriatric patients with TRD.